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Abstract
Background: MicroRNAs (miRNA) are small non-coding RNAs that regulate translation of mRNA and protein. Loss or
enhanced expression of miRNAs is associated with several diseases, including cancer. However, the identification of
circulating miRNA in healthy donors is not well characterized. Microvesicles, also known as exosomes or microparticles,
circulate in the peripheral blood and can stimulate cellular signaling. In this study, we hypothesized that under normal
healthy conditions, microvesicles contain miRNAs, contributing to biological homeostasis.
Methodology/Principal Findings: Microvesicles were isolated from the plasma of normal healthy individuals. RNA was
isolated from both the microvesicles and matched mononuclear cells and profiled for 420 known mature miRNAs by real-
time PCR. Hierarchical clustering of the data sets indicated significant differences in miRNA expression between peripheral
blood mononuclear cells (PBMC) and plasma microvesicles. We observed 71 miRNAs co-expressed between microvesicles
and PBMC. Notably, we found 33 and 4 significantly differentially expressed miRNAs in the plasma microvesicles and
mononuclear cells, respectively. Prediction of the gene targets and associated biological pathways regulated by the
detected miRNAs was performed. The majority of the miRNAs expressed in the microvesicles from the blood were predicted
to regulate cellular differentiation of blood cells and metabolic pathways. Interestingly, a select few miRNAs were also
predicted to be important modulators of immune function.
Conclusions: This study is the first to identify and define miRNA expression in circulating plasma microvesicles of normal
subjects. The data generated from this study provides a basis for future studies to determine the predictive role of
peripheral blood miRNA signatures in human disease and will enable the definition of the biological processes regulated by
these miRNA.
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Introduction
MicroRNAs (miRNAs) are small non-coding RNA sequences of
about 22 nt [1]. miRNAs have been identified in animals, plants and
viruses [2]. To date, advances in methodology have led to the
identification of 587 human miRNAs (Sanger updated database [3]),
and it is estimated that over 30% of human genes are targeted by
these miRNAs [4]. miRNAs are implicated in fundamental cellular
processes including hematopoietic differentiation [5,6], cell cycle
regulation [7,8] and metabolism [9,10]. The evolutionary conserved
miRNAs are transcribed by polymerase II and function as post-
transcriptional gene regulators by targeting messenger RNA (mRNA)
or proteins [11]. All precursor miRNA have stem loop structures,
cleaved by Drosha and Dicer, to form the mature functional miRNA.
Through formation of RNA-induced silencing complexes, miRNAs
can either cleave maturemRNAmolecules or inhibit their translation
thus representing a newly discovered layer of gene regulation.
MiRNAs play an important role in disease progression and
carcinogenesis [12,13]; MiRNAs can act as oncogenes or tumor
suppressors [14]. A study led by Calin et al. first revealed the
connection between miR-15 and -16 and B-cell chronic
lymphocytic leukemia [15]. Later, several studies showed the
importance of miRNA in prognosis, initiation and progression of
numerous cancer types [16–18]. Hence, utilizing miRNA
fingerprinting as a novel diagnostic, prognostic and disease
surveillance tool is of increasing importance [19].
PLoS ONE | www.plosone.org 1 November 2008 | Volume 3 | Issue 11 | e3694Recent evidence reveals that genetic exchange of mRNA and
miRNA between cells can be accomplished through microvesicles,
or exosome-mediated transfer [20]. Microvesicles are small
exosomes/vesicles of endocytic origin released by normal healthy
or damaged cell types [21–23]. Alternative names for microvesicles
provide insight into their source. Microparticles are microvesicles
released from activated platelets; exosomes are microvesicles
secreted by tumors; and ectosomes are neutrophil-derived
microvesicles [23]. Current estimates of microvesicle concentra-
tion in the peripheral blood of healthy individuals are 5–50 mg/ml.
Microvesicles are shed from the plasma membrane into the
extracellular environment to facilitate communication between
cells. Despite their small size (50 nm to 1 mm) microvesicles are
enriched in bioactive molecules and contain nucleic acid and/or
protein; these cell particles play a role in growth, differentiation
and cancer progression [24]. Tumor-derived microvesicles transfer
mRNA to monocytes within the tumor microenvironment to
activate these cells to produce cytokines to enhance tumor growth
and dampen the immune response [25]. Deregibus et al report
that mRNA from endothelial-derived MV are pro-angiogenic
[26]. In the peripheral blood, two-thirds of microvesicles are
derived from platelets. Platelet-derived microvesicles play a role in
angiogenesis and the metastatic spread of cancers such as lung
cancer [27]. Platelet-derived microvesicles induce an immune
response upon regulating gene expression in hematopoietic,
endothelial, and monocytic cells [28,29]. Notably, platelet-derived
microvesicle subpopulations are increased in patients with sepsis
[30,31], whereas patients with pulmonary arterial hypertension
have increased endothelial-derived microvesicles [32]. However it
is currently unknown whether microvesicle content changes in
theses diseases.
Interestingly, a connection between microvesicles and miRNA
has been recently made. Recently, Valadi and colleagues reported
that vesicles released from human and murine mast cell lines
contain over 1200 mRNA and approximately 121 miRNA
molecules [20].
Considerable evidence demonstrates the importance of miRNA
as an inevitable cornerstone of the human genetic system.
Employing the use of microvesicles to transfer genetic material
would be an efficient transfer method within the human body.
Microvesicles containing miRNAs would enable intercellular and
inter-organ communication in the body. Here, we explored the
hypothesis that miRNAs are contained within microvesicles in the
peripheral blood. We examined the expression of miRNAs from
the peripheral blood microvesicles and PBMC from normal
human volunteers. Our study identifies miRNAs in circulating
microvesicles in the plasma and in PBMC and characterizes
specific miRNA expression.
Methods
Blood collection and microvesicle isolation
Peripheral blood (40 cc) was collected in EDTA tubes from 24
female and 27 male healthy non-smoking Caucasian donors
following informed consent. Written consent was obtained from all
subjects in accordance with approved Institution Review Board
protocol (1978H0059) and HIPAA regulations. Criteria for
volunteers consist of no recent illness or treatment for a chronic
medical condition. No medical history was obtained from donors.
Collection of the blood occurred between morning and early
afternoon. The average age for female and male donors was
35612 and 3169, respectively, while the median age for both
female and male donors was 29. The peripheral blood was diluted
1:1 with sterile low endotoxin PBS (Mediatech, Inc. Manassas,
VA), layered over ficoll-hypaque (d=1.077) (Mediatech, Inc.), and
centrifuged as previously described [33]. The mononuclear cell
fraction was washed once in PBS. The microvesicles were purified
from the plasma. Briefly, the vesicles were concentrated by
centrifugation at 160,0006 g for 1 hr at 4uC [34]. To isolate
platelets, blood was collected in 3.8% sodium citrate tubes from six
donors, using a washing method as previously described [35,36].
Following centrifugation of the blood, the platelet rich plasma was
incubated with 1 mM of PGE1 (Sigma-Aldrich, St. Louis, MO).
The platelets were washed twice in Tyrodes buffer containing
138 mM NaCl, 2.9 mM KCl, 12 mM NaHCO3, 0.36 mM
NaHPO4, 5.5 mM glucose, 1.8 mM CaCl2, and 0.49 mM MgCl2,
pH 6.5. The platelets were then washed one additional time in
Tyrodes buffer, pH 7.4.
RNA Extraction
Total RNA was isolated by Trizol (Invitrogen, Carlsbad, CA)
extraction method. To increase the yield of small RNAs, the RNA
was precipitated overnight. RNA concentration and RNA
integrity were determined by capillary electrophoresis on an
Agilent 2100 Bioanalyzer (Agilent Technologies, Inc, Santa Clara,
CA). We recovered an average 1.740 mg of total RNA from the
plasma fractions. For RNA isolated from mononuclear cells, only a
RNA integrity number (RIN)$9 was used along with its matched
plasma sample for profiling. Since the intact 18s and 28s rRNA
were variable in the microvesicles, the RIN was not a constraint
for these samples, however we observed a RIN between 2–8.
miRNA profiling by quantitative PCR
At the time of the study, commercially available primers were
available for 420 mature human miRNAs. We used these looped
primers to profile 420 mature miRNAs by real-time PCR using an
Applied Biosystems 7900HT real-time PCR instrument equipped
with a 384 well reaction plate. RNA (500 ng) was converted to
cDNA by priming with a mixture of looped primers (Mega Plex
kit, Applied Biosystems, Foster City, CA) using previously
published reverse transcription conditions [37]. As there is no
known control miRNA in microvesicles, several internal controls
were examined. Primers to the internal controls, small nucleolar
(sno)RNA U38B, snoRNA U43, small nuclear (sn)RNA U6 as well
as 18S and 5S rRNA were included in the mix of primers. Liquid-
handling robots and the Zymak Twister robot were used to
increase throughput and reduce error. Real-time PCR was
performed using standard conditions.
Flow Cytometry
Peripheral blood microvesicles were directly immunostained
from plasma without concentration by centrifugation. To
determine the cellular origin, 0.5 cc plasma was immunostained
per panel of antibodies. Panel I contained antibodies recognizing
CD66b-FITC (neutrophil) (BD Biosciences, San Jose, CA),
CD202b (Tie2)-PE (endothelial) (R&D Systems, Minneapolis,
MN), CD206 PE-Cy5 (macrophage/dendritic) (BD Biosciences),
CD79a-APC (B-cell) (BD Biosciences), and CD14 Pe-Cy7
(monocyte) (BD Biosciences). Panel II contained antibodies to
CD41a-PE-Cy5 (platelet) (BD Biosciences), CCR2-APC (mono-
cyte) (R&D Systems), CCR3-PE (dendritic cell) (Caltag, Carlsbad,
CA), CCR5-PE-Cy7 (macrophage) (BD Biosciences), and CD3-
Alexa 610 (T-cell) (BD Biosciences). Panel III contained isotype
control antibodies (BD Biosciences). All antibodies were used
according to manufacturers’ recommendation. To confirm that
the microvesicles were the correct size, flow cytometry gates were
set using 2 micron bead standards (BD Biosciences). The samples
miRNAs in Blood Microvesicles
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were expressed as percent of gated events.
Statistical analysis
Since CT scores greater than 35 are considered non-specific [37],
miRNAs in which 80% of individual observations had a raw CT
score greater than 35 were not included in the final data analysis.
Using these filtering criteria, we removed 128 and 152 miRNAs for
the plasma and PBMC samples, respectively, from analysis. The
internal controls (18S, 5S, snoRNA U38B, snoRNA U43, and
snRNA U6) were highly variable in the plasma microvesicles and
were significantly different in plasma microvesicles versus peripheral
blood mononuclearcells (PBMC). To reducebiascaused byusing an
arbitrary miRNA as a normalization correction factor, the miRNAs
were compared between plasma microvesicles and PBMC based on
their relative expression to the overall miRNA expression on each
array using median normalization analysis [33]. To test the
difference of specific miRNA between plasma microvesicles and
PBMC, linear mixed models were used and p-values were generated
from the model based on the estimated difference and sample
variation. Fold-change was calculated based on the estimated mean
difference (2
^(2DCT)). MiRNAs were subjected to hierarchical
clustering using Euclidean distance based on their relative mean
expression. MiRNAs were also ranked based on their raw CT score
for each plasma microvesicles and PBMC.
Pathway analysis and prediction
Predicted miRNA targets were determined using the miRanda
algorithm (http://microrna.sanger.ac.uk/targets/v5/) and Tar-
getScan v4.2 (http://www.targetscan.org/). Common predicted
targets as well as targets from each database were subjected to
pathway exploration using the Ingenuity Pathway Analysis (IPA)
software (Ingenuity Systems, Redwood City, CA). To avoid
exceeding the maximum gene list size allowed by IPA program, we
limited targets based on each programs assigned score. Therefore
scores of at least 17 and 20.31 were considered for miRanda and
TargetScan, respectively. Using this software and its accompany-
ing interaction database, top-ranked pathways were determined
based on the incidence of predicted miRNA targets in a list of
canonical pathways provided by the software. IPA also generates
the top-ranked networks where the predicted miRNA targets are
found; according to gene ontology, the biological functions
associated with these networks are provided.
Results
Peripheral blood microvesicle subpopulations
To ensure that our isolation method purified microvesicles, we
examined size of the microvesicles by flow cytomtery. To visualize
the microvesicles by flow cytometry, the axis for forward scatter
(FSC) vs. side scatter (SSC) plot required log-scale (Figure 1A). Flow
cytometry gates were set using 2 micron beads (Figure 1A, inset).
Notably, the size of the microvesicles analyzed in this study was in
therangeofthebeadstandards.Wealsoexaminedthecellularorigin
of microvesicles within the peripheral blood of normal healthy
individuals. Using flow cytometry, we found that the majority of the
peripheral blood microvesicles are platelet-derived (Figure 1B), as
previously reported [34]. We also observed a second large
population of microvesicles that were derived from mononuclear
phagocyte cell lineage. This population was immunostained with
antibodies that detected surface antigens on mononuclear phago-
cytes. Notably, only a small percentage of the peripheral blood
microvesicleswerederivedfromT-cellsandneutrophils.Wefailedto
detect vesicles that originated from B-cells (data not shown). Of
interest, we detected a small subpopulation of microvesicles that
expressed surface antigens from endothelial cells.
miRNA expression in plasma microvesicles and PBMC
To test our hypothesis that miRNAs are contained in the
microvesicle compartment within the peripheral blood to enable
communication and influence genetic changes between different
tissues within the body, we performed miRNA profiling on the
purified microvesicles from all cellular origins in the plasma. We
analyzed all subpopulations of microvesicles from 51 non-smoking
healthy individuals comprising of 27 males and 24 females. Since
we hypothesized that there would be differences in miRNA
expression between microvesicles and PBMC, we also purified the
PBMC from each donor. Real-time PCR analysis was performed
to examine the expression of 420 miRNAs. Expression of the
internal controls (18S, 5S, snoRNA U38B, snoRNA U43, and
snRNA U6) was highly variable in the plasma microvesicles versus
peripheral blood mononuclear cells (PBMC) (Figure 2A and 2B).
To reduce bias caused by using an arbitrary miRNA as a
normalization correction factor and to reduce the sample
variations among qRT-PCR arrays, the miRNAs were compared
Figure 1. Analysis of the origin of peripheral blood microves-
icles. Peripheral blood microvesicles from healthy donors (n=10) were
analyzed by flow cytometry. (A) The size of the microvesicles was
determined by FSC vs. SSC. The gate was set according to 2 micron
beads (inset). (B) To determine cell origin, microvesicles were stained
for CD3, CD202b (Tie-2), CD66b, CD79a, or CD41a to determine those
that originated from T-cells, endothelial cells, neutrophils, B-cells, or
platelets. Mononuclear phagocyte-derived microvesicles were positive
for CD14, CD206, CCR3, CCR2, or CCR5. Shown is the average %
maximum of total gated events6S.E.M.
doi:10.1371/journal.pone.0003694.g001
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expression to the overall miRNA expression on each array using
median normalization analysis (Figure 2C) [33]. The filtered and
normalized data were subjected to hierarchical cluster analysis
comparing the miRNA expression profile between the PBMC and
plasma microvesicles samples (Figure 3). All but three PBMC
samples clustered separately from the microvesicle samples
indicating that the miRNA expression profile between the two
groups was significantly different. It is not readily apparent why
three samples clustered differently. These donors varied in age and
gender. However, based on filtering criteria, we found 104 and 75
miRNAs were significantly expressed in microvesicle and PBMC
samples, respectively (Figures 4A and 4B). Of these miRNAs, 71
were co-expressed among each sample group (Figure 4C).
Age and gender effects
We did not observe age and/or gender effects in miRNA
expression from either sample group or across PBMC and plasma
microvesicles samples. Notably, the median age for both female
and male donors was 29 years. The oldest individual was 58 years
old, while the youngest was 21 years of age. Thus, we further
stratified the data to examine differences. For each PBMC and
microvesicles compartment, we also compared the miRNA
expression of the donors with the upper quartile of age to those
with the lower quartile of age (mean age for each group was
48.966.2 and 21.961.2, respectively). However, we failed to
detect significant differences in miRNA expression between the
samples sets based on age (data not shown).
Comparison of miRNA expression in PBMC and
microvesicles
In Table 1, miRNA expression was analyzed separately in plasma
microvesicles and PBMC to determine the most highly expressed
miRNAs and to determine the frequency of expression across all
donors. Normalized expression for all miRNAs in the plasma
microvesicles and PBMC from all tested individuals can be found in
TableS1.miR-223,-484,-191,-146a,-16,-26a,-222,-24,-126,and
-32 were detected in plasma microvesicles, while miR-150, -146b,
Figure 2. Distribution of miRNA expression. The box plots were generated to demonstrate the distribution of miRNA expression from each
PBMC and plasma microvesicle sample. The bottom and top of the boxes are the 25
th and 75
th percentile (the lower and upper quartiles,
respectively), and the band near the middle of the boxes are the 50
th percentile (the median). The ends of the whiskers represent the minimum and
maximum of the data. (A) Raw CT score of the data from individual donor were plotted. (B). 18s standardized data (DCT ) were plotted: DCT=raw CT of
PBMC or plasma microvesicles – CT of 18S. (C). Median normalized data of each donor was used.
doi:10.1371/journal.pone.0003694.g002
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but not in plasma microvesicles. In contrast, the PBMC samples,
shared 6 common miRNAs with plasma microvesicles (miR-223,
-484,-191,-146a,-16,and-26a).PBMCsalsolackedhighexpression
of miR-222, -24, -126, and -32 in the top expressed miRNAs
compared to those found in plasma microvesicles.
Based on ranking analysis, miR-223 was the most highly
expressed miRNA in both PBMC and plasma microvesicles. We
next hypothesized that miRNAs originating from specific organ
sites would be detected in the PBMC or plasma microvesicles. Lee
et al reported that miR-122a is specifically expressed in liver tissue
while miR-216 and miR-217 are preferentially expressed in the
pancreas [38]. Interestingly these miRNAs were not identified in
the plasma microvesicles (Table S1).
We next examined the predicted function of the most highly
expressed miRNAs in the plasma microvesicles and PBMC. We
examined the top nine expressed miRNAs from the plasma
microvesicles and PBMC samples. Using the Sanger miRBase
Target v5 and TargetScan v4.2, we found 1578 and 1899
predicted targets, respectively, for the group of highly expressed
miRNAs from plasma microvesicles (Table S2). Merging targets
from the two databases, we found 94 common predicted targets.
These combined targets were subjected to computational analysis
to predict pathways that they would collectively regulate. Using
Ingenuity Pathway Analysis (IPA) software, we found canonical
pathways involved in metabolism, estrogen receptor signaling, and
degradation of phospholipids that were predicted to be highly
regulated by these miRNAs (Table 2). Of the nine miRNAs
examined from the PBMC fraction, we found 1857 and 2072
predicted mRNA targets from Sanger miRBase and TargetScan
database, respectively (Table S2) and 89 common targets (Table
S2). The top five canonical pathways expected to be regulated by
Figure 3. miRNA expression from peripheral blood microvesicles and PBMC. Hierarchical cluster analysis for microvesicles and PBMC is
shown based on filtering criteria. The (*) denotes the three PBMC samples which clustered with the plasma microvesicle samples.
doi:10.1371/journal.pone.0003694.g003
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metabolic pathways, among others (Table 2).
We next examined miRNAs that were differentially expressed
between plasma microvesicles and PBMC. We found 22 miRNAs
had more than a two-fold increase in expression in the PBMC
fraction compared to the plasma microvesicles samples, and
among them, 15 miRNAs had more than 3-fold changes
compared to PBMC (Table 3, Table S3). Interestingly, none of
these differentially expressed miRNAs in plasma microvesicles
were identified as tissue-specific miRNAs. As shown in Table 3,
miR-486 is the highest differentially expressed miRNA in the
plasma microvesicles compared to PBMC. The canonical
pathways predicted to be regulated by miR-486 are phenylalanine
and cyanoamino acid metabolism, insulin receptor signaling,
antigen presentation, and pentose phosphate pathways.
Comparison of miRNA expression in platelet and plasma
microvesicles
Since the majority of plasma microvesicles were platelet-
derived, we also isolated platelets from several of the donors
(n=6) to profile miRNA expression. We found 52 co-expressed
miRNAs in plasma microvesicles and platelets, while there were
many more miRNAs unique to the plasma microvesicles
compared to platelets (Figure 5). As shown in Table 4, there are
many similarities between the platelets and the plasma microves-
icles and PBMC. One striking observations is that miR-223 is also
Figure 4. Expression profile of common miRNAs. Heat-maps demonstrating the expression profile for microvesicles (A) and PBMC (B) were
generated for miRNAs that were commonly expressed. (C) The number of shared and specific miRNAs for each sample group is shown.
doi:10.1371/journal.pone.0003694.g004
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observe the expression of miR-484 in the platelets, which is found
in both plasma microvesicles and PBMC.
Discussion
In this study, we hypothesized that miRNAs circulate in plasma
microvesicles, platelets, and PBMC of normal human volunteers in
the peripheral blood. We have characterized peripheral blood
miRNA patterns in healthy humans. We found significant differences
in miRNA expression between plasma microvesicles, platelets, and
PBMC. To date, numerous studies have established the ability for
miRNAs to regulate many cellular functions. However, these studies
largely imply that the miRNA resides within its host cell to elicit an
effect [39]. Our data indicate that the miRNAs are also contained in
plasma microvesicles that may influence homeostasis.
The defined mechanism or cellular signals that regulate
microvesicle production is unknown. Some suggest that the vesicle
‘‘hijacks’’ the cytoplasm prior to release from the cell through
membrane blebbing [23]. This paradigm suggests that packaging
of the miRNAs in the microvesicle may be random. Alternatively,
endosomal trafficking may modulate the formation of microves-
icles [40]. Since P-bodies in the cytoplasm co-localized with
miRNAs [2,4], we are exploring whether P-bodies may regulate
the transfer and sorting of miRNAs into vesicles. There are other
reports of tumor cell fragments containing miRNAs in the plasma
and/or serum [41,42]. Recently Taylor and colleagues found
circulating tumor microvesicles in the peripheral blood of patients
with ovarian cancer but not healthy individuals [41]. These
microvesicles express miRNAs found in the primary tumor.
It is conceivable that the miRNAs in the plasma microvesicles
circulate to tissue targets. Further examination of the highest
expressed miRNAs in plasma microvesicles (Table 1), demonstrate
that many of these miRNA are predicted to regulate hematopoi-
esis and cellular differentiation. For instance, expression of miR-
223 is predicted to influence myeloid, granulocyte and osteoclast
differentiation [43–45]. miR-223 also appears to have a role in
hematopoietic stem cell proliferation [43]. Interestingly, miR-223
expression is lost in acute myelogenous leukemia (AML) [46].
miR-24 expression is regulated by TGF-b, a potent positive and
negative regulator of hematopoiesis [47,48]. Both miR-24 and
miR-16 regulate red cell production [49,50], while miR-16 also
modulates lymphoid development [51]. Loss of miR-16 expression
has been extensively examined in chronic lymphocytic leukemia
(CLL) [52,53]. In contrast, downregulation of miR-126 expression
occurs during megakarocyte differentiation [54].
Table 1. Normalized expression and rank analysis of miRNAs in plasma microvesicles or PBMC.
Plasma Microvesicles PBMC
miRNA
Normalized
Expression
(6S.D.)
Frequency
Detected Among
Donors (%)
Top Ten
Ranking (%) miRNA
Normalized
Expression
(6S.D.)
Frequency
Detected Among
Donors (%)
Top Ten
Ranking (%)
miR-223 15896653 100 100 miR-223 21436499 100 100
miR-484 50.9622.9 100 96 miR-150 241694.6 98 98
miR-191 46.4614.9 100 100 miR-146b 57.5621.1 100 100
miR-146a 39.5619 100 88 miR-016 54.7632.9 100 100
miR-016 25.4613.3 100 78 miR-484 40.6618.8 89 88
miR-026a 25.269.95 100 90 miR-146a 39.6613.0 100 98
miR-222 24.5612.4 100 76 miR-191 32.4615.6 100 94
miR-024 22.7610.5 100 80 miR-026a 3068.92 100 100
miR-126 18.268.04 100 66 miR-019b 21.767.49 100 80
miR-032 15.3632.6 100 31 miR-020a 1565.11 100 4
Expression of miRNAs in the plasma microvesicles and PBMC were analyzed separately (n=51). The normalized miRNA expression was generated using median
normalization analysis then the mean CT value was converted to expression (2
^(2DCT)) 6standard deviation (S.D.). Shown is the ‘‘Frequency Detected Among Donors’’
represents the percentage of donors in which the miRNA was detectable by qRT-PCR. The ‘‘Top Ten Ranking’’ indicates the percentage of individuals in which the
normalized expression for each miRNA fell within the top ten highly expressed miRNAs.
doi:10.1371/journal.pone.0003694.t001
Table 2. Predicted pathways regulated by miRNAs expressed in the plasma microvesicles and PBMC fractions.
Plasma Microvesicles p-value PBMC p-value
glycerophospholipid metabolism 3.29E-03 axonal guidance signaling 1.47E-02
inositol phosphate metabolism 5.77E-03 synaptic long-term potentiation 2.07E-02
phospholipid degradation 9.17E-03 estrogen receptor signaling 2.23E-02
alanine and aspartate metabolism 1.96E-02 glycerophospholipid metabolism 2.45E-02
estrogen receptor signaling 2.14E-02 D-glutamine and D-glutamate metabolism 2.78E-02
Predicted targets were compiled separately using Sanger miRBase and TargetScan for the top nine miRNAs expressed in the plasma microvesicles and PBMC (Table 1).
The common predicted targets were subsequently analyzed by IPA software to determine predicted pathways regulated by the miRNAs. Fisher’s exact test was used to
calculate a p-value determining the probability of the association between the genes in the dataset and the canonical pathway.
doi:10.1371/journal.pone.0003694.t002
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regulate the progression of the cell cycle proteins [55,56]. miR-222
targets p27Kip1 [55] while miR-24 suppresses p16 (INK4a) [56].
Increased expression of miR-16 results in the accumulation of cells
in G0/G1 phase of the cell cycle [47].
To date, there are no known functions for miR-484 which is the
second highest expressed miRNA in the plasma microvesicles
fraction based on normalized expression (Table 1). Using IPA
analysis, miR-484 appears to regulate hematopoiesis, as well as
cellular differentiation, proliferation and growth similar to many of
the highly expressed miRNAs in the plasma microvesicles. Another
of the highly expressed miRNAs, miR-146a is predicted to modulate
NK cell signaling and IL-4 signaling pathways. Similarly, miR-146a
isalsopredictedtoregulate immune functions[57,58].BasedonIPA
analysis examining gene ontology of targets, the top associated
networks predicted to be influenced by miR-146a expression are
cellular proliferation, immune and lymphatic system development
and function. In addition,this miRNA is predicted to regulate innate
immune responses. From the analysis, we found that LPS/IL-1 and
toll-likereceptorsignalingareamongthetopfivecanonicalpathways
predicted to be regulated by miR-146a.
Comparison of differentially expressed miRNAs between the
plasma microvesicles and the PBMC indicated that miR-486 was
the highest differentially expressed in the plasma microvesicles
(Table 3). Little is known about this miRNA, except that it is
expressed in glioblastoma cells and may function in brain cell
differentiation [59]. Analyzing the predicted targets from Sanger
miRBase with the IPA software, the top five canonical pathways
predicted to be regulated by miR-486 are those in phenylalanine
and cyanoamino acid metabolism, insulin receptor signaling,
antigen presentation, and pentose phosphate pathways. Another
miRNA differentially expressed in the plasma microvesicles is
miR-328. Recently, Wang and colleagues reported that miR-328
is important in regulating tumor development and invasion by
targeting CD44 expression in epithelial carcinoma cell lines [60].
Overexpression of miR-328 inhibits cell migration and adhesion
and preventing them to expand into the tumor.
The majority of the plasma microvesicles from normal
individuals are derived from blood cells. We did detect a small
Table 3. Comparison of miRNA expression between plasma microvesicles and PBMC.
Expression in Plasma
Microvesicles Fold Change p-Value Expression in PBMC Fold Change p-Value
miR-486 6.742 4.31E-20 miR-150 59.93 7.00E-21
miR-328 6.602 1.64E-21 miR-029a 40.31 9.69E-28
miR-183 5.979 7.17E-08 miR-142-3p 23.49 1.90E-22
miR-032 4.530 8.52E-09 miR-146b 22.85 1.81E-22
miR-574 4.390 3.05E-06 miR-155 9.252 6.61E-23
miR-027b 4.208 1.20E-05 miR-532 4.730 6.14E-10
miR-222 3.995 1.18E-21 miR-019a 4.682 2.85E-12
miR-197 3.783 5.34E-18 miR-140 4.219 2.87E-17
miR-151 3.482 2.24E-21 miR-021 4.211 4.23E-08
miR-199a* 3.454 3.21E-09 miR-374 3.769 8.00E-15
miR-133b 3.348 4.05E-06 miR-181d 3.713 5.30E-07
miR-320 2.637 1.63E-16 miR-345 3.670 1.25E-08
miR-096 2.270 3.86E-4 let-7g 3.247 4.99E-09
miR-103 2.190 1.99E-08 miR-015a 3.226 3.24E-07
miR-017-5p 2.037 1.26E-07 miR-019b 3.213 7.11E-12
miR-142-5p 2.671 9.83E-08
miR-106b 2.491 1.28E-07
miR-016 2.392 1.35E-10
miR-026b 2.307 5.44E-06
miR-195 2.243 5.50E-5
In order to test the differences of miRNA expression between plasma microvesicles and PBMC, data were analyzed using linear mixed models. The p-values were
generated from the model based on the estimated difference and sample variation. A bonferroni adjustment for multiple comparisons (72 comparisons) to control type
I error to reduce the number of false positives was performed, therefore ‘‘p-value’’ was considered as significant if p-value,0.05/72=0.0006. Fold-change was calculated
based on the estimated mean difference (2
^(2DCT)). Shown are miRNAs that were significantly expressed at greater than 2-fold.
doi:10.1371/journal.pone.0003694.t003
Figure 5. Venn diagram comparing miRNA expression in
platelets and plasma microvesicles. The number of shared and
specific miRNAs for each sample group is shown.
doi:10.1371/journal.pone.0003694.g005
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human endothelial progenitor cells can produce microvesicles in vitro
[26], detection of the endothelial derived vesicles in circulation is of
interest. We would predict that the endothelial-derived microvesicles
may increase upon endothelial cell damage. Recently, elevation of
endothelial-derived microvesicles has been reported in patients with
pulmonary arterial hypertension [32], however their content is
currently unknown. Likewise, the detection of tissue specific
miRNAs and microvesicles in the peripheral blood may be a
frequent event upon tissue damage. The detection of tumors
exosomes (microvesicles) have been found in the peripheral blood to
contain miRNAs [41]. Interestingly, comparing this paper’s findings
withourdata,18elevatedtumor-derived miRNAswerenot detected
in the plasma from our normal donors (Table S1).
While it has been reported that miRNAs are detected in the
plasma [41,42,61–63], this is the first study to profile miRNAs from
the plasma microvesicles in a normal healthy population. Since our
study was limited to Caucasians, we do not know the influence of
race or ethnicity. In this study, we also examined whether miRNA
expression in the plasma microvesicles was influenced by age.
Surprisingly, we observed no difference between gender and age in
our study. These are important factors as we and others examine
miRNA expression from the plasma and/or serum in various
diseases to serve as diagnostic biomarkers.
Our findings indicate that miRNAs circulate in the plasma and
PBMC of normal donors. These miRNAs are predicted to regulate
homeostasis of hematopoietic cells and of metabolic function.
Investigations are currently underway to understand if specific
cells are targeted by the plasma microvesicles and determine the
influence of these microvesicle-containing miRNA on target cell
mRNA expression. We predict that the plasma microvesicles may
be selective in their target cells. For instances, platelet-derived
microparticles transfer tissue factor to monocytes but not
neutrophils [64]. Thus, we predict that the defined function of
each subpopulation of the plasma microvesicles and their miRNAs
will be important factors in the regulation of immune responses
and hematopoiesis.
Supporting Information
Table S1 Normalized expression for plasma microvesicles and
PBMC. Expression of miRNAs in the plasma microvesicles and
PBMC were analyzed separately (n=51). The normalized miRNA
expression was generated using median normalization analysis
then the mean CT value was converted to expression (2^(2del-
taCT)) 6standard deviation (S.D.).
Found at: doi:10.1371/journal.pone.0003694.s001 (0.01 MB PDF)
Table S2 Predicted targets for miRNAs expressed in the plasma
microvesicles and PBMC. Predicted targets were compiled
separately using Sanger miRBase and TargetScan for the top
Table 4. Normalized miRNA expression in platelets.
detector_name
Average Normalized
Expression
Standard
Deviation
miR-484 21.079 5.936
miR-191 19.282 2.716
miR-146a 14.438 4.915
miR-016 12.851 3.097
miR-026a 11.325 2.159
miR-126 10.944 4.664
miR-024 8.910 2.883
miR-020a 7.392 1.640
miR-019b 7.287 2.611
miR-222 6.626 2.071
miR-032 5.551 5.855
miR-486 4.510 3.876
miR-643 4.391 4.507
miR-150 2.408 2.029
miR-096 2.113 3.044
miR-146b 1.936 0.538
miR-574 1.832 0.631
miR-140 1.695 0.268
miR-151 1.607 0.670
miR-093 1.543 0.738
miR-183 1.421 2.232
miR-092 1.418 0.581
miR-142-3p 1.364 0.602
miR-328 1.298 0.324
miR-019a 1.195 0.514
miR-030c 1.124 0.411
miR-186 1.096 0.346
miR-197 1.092 0.447
miR-030b 1.040 0.243
miR-017-5p 1.007 0.270
miR-331 0.930 0.312
miR-125a 0.807 0.368
miR-015b 0.796 0.178
miR-126* 0.752 0.291
miR-026b 0.477 0.294
miR-342 0.475 0.344
miR-628 0.413 0.431
miR-106a 0.395 0.248
miR-142-5p 0.360 0.222
miR-320 0.330 0.149
let-7b 0.290 0.142
miR-030a-5p 0.271 0.141
miR-106b 0.247 0.185
miR-182* 0.225 0.161
miR-374 0.224 0.196
miR-027a 0.203 0.160
miR-030d 0.158 0.096
miR-423 0.124 0.096
Table 4. cont.
detector_name
Average Normalized
Expression
Standard
Deviation
miR-021 0.120 0.111
miR-195 0.116 0.078
miR-133b 0.104 0.072
Normalized expression of miRNAs in the platelets (n=6) was calculated using
median normalization analysis then the mean CT value was converted to
expression (2
^(2DCT)) 6standard deviation (S.D.).
doi:10.1371/journal.pone.0003694.t004
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(Table 1). Targets were common between the databases were
furthered analyzed for predicted function.
Found at: doi:10.1371/journal.pone.0003694.s002 (0.20 MB PDF)
Table S3 Comparison of miRNA expression between plasma
microvesicles and PBMC. In order to test the differences of miRNA
expression between plasma microvesicles and PBMC, data were
analyzed using linear mixed models. The p-values were generated
from the model based on the estimated difference and sample
variation. A bonferroni adjustment for multiple comparisons (72
comparisons) to control type I error to reduce the number of false
positives was performed, therefore ‘‘p-value’’ was considered as
significant if p-value,0.05/72=0.0006. Fold-change was calculated
based on the estimated mean difference (2^(2DCT)).
Found at: doi:10.1371/journal.pone.0003694.s003 (0.01 MB PDF)
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